4 Heathcare Stock Stories Attracting Investor Attention

Biodel (NASDAQ:BIOD) Current price $2.70

On Thursday, the firm reported positive top-line results from a Phase 1 clinical trial of two ultra-rapid-acting insulin analog-based formulations, BIOD-238 and BIOD-250, conducted to study the pharmacokinetic and injection site toleration profiles relative to Humalog, which is a quickly-acting insulin analog. BIOD-238 and BIOD-250 are combinations of Biodel’s proprietary excipients with the marketed formulation of Humalog.


Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

Auxilium Pharmaceuticals (NASDAQ:AUXL) Curremt price $18.27

The biopharmaceutical firm announced that it intends to offer a $200.0 million aggregate principal amount of Convertible Senior Notes due 2018 in an offering registered under the Securities Act of 1933, as amended. The Convertible Notes are expected to pay interest semi-annually and be convertible into shares of Auxilium’s common stock, cash or a combination thereof at the firm’s election.


Health Net (NYSE:HNT): Current price $27.08

The firm’s subsidiaries of the firm reached on Thursday a new multi-year agreements that allow Health Net members access to medical care at all 11 Tenet Healthcare Corporation (NYSE:THC) hospitals in California. Along with covering Tenet’s 11 facilities statewide, the new arrangements reinstate and retroactively cover Tenet Healthcare’s six Southern California hospitals that were terminated from the Health Nets network on December 22nd, as if there had been no termination.


Solazyme (NASDAQ:SZYM) Current price $7.45

Solazyme announced Thursday the closing of its offering of 6 percent Convertible Senior Subordinated Notes due 2018 in a private offering. The issuance of $125 million aggregate principal amount of notes includes the exercise in full by Goldman Sachs, the sole book-running manager for the offering, of its option to buy $10 million aggregate principal amount of notes to cover over-allotments. The firm received aggregate net proceeds of around $119.4 million, and it intends to use the net proceeds of the offering to fund project related costs and capital expenditures and for general corporate purposes.


Don’t Miss: IPOs, Lawsuits, and Cancer Treatments: Healthcare Recap.